<DOC>
	<DOCNO>NCT00737438</DOCNO>
	<brief_summary>This study do find effective new treatment strategy cancer . In strategy , response tumor first cycle therapy help select next treatment . We also find effect , good and/or bad , drug call bevacizumab tumor give chemotherapy .</brief_summary>
	<brief_title>Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based PET Assessment Response Patients With Locally Advanced But Resectable Gastric GEJ Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>All patient must microscopically confirm adenocarcinoma stomach GE junction . Tumors involve GE junction must bulk disease stomach ; tumor distal esophagus extend less 2cm stomach ineligible study . All patient must consider candidate surgical resection . Patients must FDGavid malignancy . FDG avid tumor define primary tumor increase tracer uptake region tumor SUV &gt; = 3.5 tumor : liver ratio &gt; = 1.5 , felt `` probably '' `` definitely malignant '' ( i.e . likelihood score 3 4 ) reference nuclear medicine physician . All patient must localize cancer potentially curable surgery . The tumor stage T N+ M0 T3T4a N M0 ( AJCC 7th Edition ) , stag include CT scan either laparoscopy endoscopic ultrasound . Patients T12 N0M0 patient distant metastatic disease ( i.e . M1 ) ineligible . Any site suspect M1 disease criterion must prove M0 prior entrance neoadjuvant study . Patients may receive prior chemotherapy radiation disease . The patient least 18 year age . If female child bear potential , patient negative serum pregnancy test within 14 day start therapy , , male female child bear potential , currently use ( agree continue use throughout study ) acceptable method birth control ( IUD , oral contraceptive , barrier device ) . They agree continue use three month study complete . The patient also agree refrain nurse duration study least two month study complete . Pregnant lactating female include antiproliferative effect bevacizumab may harmful fetus develop infant . Karnofsky performance status &gt; = 70 % . The patient adequate hematopoietic function , define total neutrophil count ( ANC ) ≥ = 1500/mm3 , platelet count ≥ = 100,000/mm3 . The patient adequate renal hepatic function , define serum creatinine ≤ = 2.5 mg/dl , urinalysis demonstrate &lt; 2+ proteinuria and/or urine protein/creatinine ( UPC ) ratio &lt; 1.0 . LFTs include total serum bilirubin ≤ = 2 x ULN , serum AST ( SGOT ) /ALT ( SGPT ) ALK PHOS &lt; = 2.5 ULN . The patient PT ( INR ) &lt; = 1.5 PTT &lt; = 3 second upper limit normal ( i.e . MSKCC PTT &lt; = 37.7 sec ) patient anticoagulation . If patient fulldose anticoagulant , follow criterion meet enrollment 1 . If use warfarin , subject must inrange INR ( usually 2 3 ) stable dose warfarin . 2 . The subject must active bleed pathological condition carry high risk bleeding ( e.g . tumor involve major vessel , know varix ) . Ability understand inform consent sign write informed consent document prior initiation treatment . Any metastatic disease . Significant cardiac disease define : New York Heart Association ( NYHA ) grade II great ( see Appendix B NYHA Class ) , congestive heart failure , history myocardial infarction unstable angina within 12 month study enrollment Any history stroke transient ischemic attack time . Pregnant ( positive pregnancy test ) lactate woman . A pregnancy test perform sexually active woman childbearing potential prior entry study . Treatment may begin result pregnancy test ascertain . Inadequately control hypertension ( define systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 mmHg ) antihypertensive therapy . Any prior history hypertensive crisis hypertensive encephalopathy . Significant vascular disease ( e.g . aortic aneurysm , aortic dissection ) Symptomatic peripheral vascular disease ( ie . grade 2 high ) . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior start therapy ( eg . day 0 ) . Core biopsy minor surgical procedure , exclude placement vascular device , within 7 day start therapy . Evidence bleed diathesis coagulopathy . Proteinuria screen demonstrate either Urine protein : creatinine ( UPC ) ratio &gt; 1.0 screening , Urine dipstick proteinuria &gt; = 2+ ( patient discover &gt; = 2+ proteinuria dipstick urinalysis baseline undergo 24 hour urine collection must demonstrate &lt; = 1g protein 24 hour eligible ) . Serious intercurrent infection , nonmalignant medical illness uncontrolled whose control may jeopardize complication therapy . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior study enrollment . Serious , nonhealing wound , ulcer , bone fracture . Grade 2 great preexist peripheral neuropathy . Psychiatric disorder render patient incapable comply requirement protocol . Any concurrent active malignancy nonmelanoma skin cancer , nonmetastatic prostate cancer carcinomainsitu uterine cervix . Patients previous malignancy without evidence disease &gt; 5 year allow enter trial . Clinically significant hearing loss . EKG evidence acute ischemia significant conduction abnormality , determine treat physician . Known hypersensitivity Chinese hamster ovary cell product , recominant human antibody , component bevacizumab . Patients medical condition reason , investigator 's opinion , make patient unsuitable participate clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>BEVACIZUMAB ( AVASTIN )</keyword>
	<keyword>CAPECITABINE ( ORAL )</keyword>
	<keyword>CISPLATIN</keyword>
	<keyword>EPIRUBICIN</keyword>
	<keyword>IRINOTECAN ( CPT-11 ) CAMPTOSAR</keyword>
	<keyword>TAXOTERE ( DOCETAXEL )</keyword>
	<keyword>ESOPHAGUS</keyword>
	<keyword>STOMACH</keyword>
	<keyword>08-081</keyword>
</DOC>